News & Updates
Showing Multidisciplinary articles
Showing
Sarcoidosis patients at risk of haematologic, nonmelanoma skin cancers
Sarcoidosis patients with biopsy-verified non-necrotizing granulomatous inflammation are at greater risk of haematologic cancers and nonmelanoma skin cancer (NMSC) in the long term than the general population, a study has found.
Dual inhibition of LAG-3, PD-1: a new therapeutic target for advanced melanoma?
In the phase II/III RELATIVITY-047 trial evaluating dual checkpoint inhibition for advanced melanoma, a new fixed-dose combination comprising the LAG-3 inhibitor relatlimab and the PD-1 inhibitor nivolumab fared better than nivolumab monotherapy.
Hypertension in pregnancy ups risk of poor delivery, infant outcomes
Hypertensive disorders in pregnancy seem to aggravate the risk of premature delivery and intrauterine growth retardation, reports a recent study. Consequentially, the delivered infants may be more likely to sustain injuries to the cardiovascular and endocrine system and suffer from neurodevelopmental delays.
Pamiparib works well against platinum-sensitive, -resistant ovarian cancer
The selective oral PARP1/2 inhibitor pamiparib is well tolerated and demonstrates favourable antitumour activity with durable responses in the treatment of patients with platinum-sensitive ovarian cancer or platinum-resistant ovarian cancer harbouring the germline BRCA mutation, according to the results of a phase II trial.
Famotidine for mild-to-moderate COVID-19 succeeds in phase II trial
Use of famotidine in the treatment of outpatients with mild-to-moderate COVID-19 is safe and well tolerated, leading to rapid resolution of symptoms and inflammation without reducing anti-SARS-CoV-2 immunity, according to the results of a phase II trial.
